Skip to main content
. 2017 Jul 19;8:481. doi: 10.3389/fphar.2017.00481

Table 1.

Information and comorbidities between pulmonary tuberculosis cases and controls.

Variable Non-tuberculosis N = 9422 Tuberculosis N = 9422 P-value*
n % n %
Sex 0.88
   Female 3,000 31.8 3,010 31.9
   Male 6,422 68.2 6,412 68.1
Age group (years) 0.99
   20–39 1,551 16.4 1,549 16.4
   40–64 3,474 36.9 3,472 36.9
   65–84 4,397 46.7 4,401 46.7
Age (years), mean (standard deviation) 59.5 (17.1) 59.6 (17.1) 0.8
Duration of exposure to proton pump inhibitors (months), mean (standard deviation) 3.49 (6.06) 3.19 (5.96) 0.13
Ever use of proton pump inhibitors 1,694 18 2,102 22.3 <0.001
Ever use of histamine-2 receptor antagonists 371 3.94 346 3.67 0.34
COMORBIDITIES
Alcohol-related disease 717 7.61 745 7.91 0.45
Asbestosis 1 0.01 1 0.01 0.99
Chronic liver disease 1,637 17.4 1,674 17.8 0.48
Chronic obstructive pulmonary disease 4,111 43.6 4,136 43.9 0.71
Chronic kidney disease 459 4.87 468 4.97 0.76
Diabetes mellitus 1,433 15.2 1,477 15.7 0.38
Human immunodeficiency virus infection 21 0.22 21 0.22 0.99
Gastrectomy 9 0.1 9 0.1 0.99
Pneumoconiosis 87 0.92 75 0.80 0.34
Splenectomy 2 0.02 2 0.02 0.99

Data are presented as the number of subjects in each group with percentages given in parentheses, or mean with standard deviation given in parentheses.

*

Chi-square test, and

t-test comparing subjects with and without pulmonary tuberculosis.